ArticleSurgical case reports2025
Evaluating Tumor Dynamics Using Circulating Tumor DNA in the Rare Cancer Anorectal Malignant Melanoma: A Report of Two Cases.
Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnorectal malignant melanoma (ARMM) is an extremely rare and aggressive cancer that lacks specific tumor markers, making tumor dynamics difficult to monitor. Circulating tumor DNA (ctDNA), which contains cancer-specific gene mutations, has emerged as a promising biomarker for monitoring various malignant tumors. We herein report the clinical utility of ctDNA measurements in 2 patients with ARMM. CASE PRESENTATION: Case 1: A 64-year-old woman diagnosed with clinical Stage III ARMM underwent laparoscopic abdominoperineal resection with lateral lymph node dissection. Pathological findings confirmed R0 resection, and genetic analysis identified a neuroblastoma RAS viral (v-ras) oncogene homologue (
conclusionsWe demonstrated the utility of ctDNA monitoring in patients with ARMM, a rare tumor. This method has the potential to be applied to other rare tumors if tumor-specific mutations can be identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.